Level A· Stronger Clinical EvidenceSystematic ReviewPubMedOpen access

Stromal vascular fraction therapy for knee osteoarthritis: a systematic review.

Boada-Pladellorens A., Avellanet M., Pages-Bolibar E., Veiga A.

Systematic Review with a reported sample of 239 on Knee Osteoarthritis, Osteoarthritis, published in Ther Adv Musculoskelet Dis (2022) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Ther Adv Musculoskelet Dis (2022)
Country
England
Reported sample size
239
Source database
PubMed
PMID
35991523
PMCID
PMC10744886
DOI
10.1177/1759720X221117879
Citations
33

Abstract (original English)

Background Regenerative cell therapies, such as adipose-derived stromal vascular fraction (SVF), have been postulated as potential treatments for knee osteoarthritis (KOA). Objectives To assess the efficacy and safety of SVF treatment against placebo and other standard therapies for treating KOA in adult patients. Design A systematic review. Data sources and methods We searched the following databases: MEDLINE via PubMed, Epistemonikos, PEDro, DynaMed, TripDatabase, Elsevier via Clinicalkey and Cochrane Controlled Trials Register. We included prospective interventional studies where treatment with SVF in adults with KOA was compared against placebo or other standard therapies, and results were objectively measured with at least one widely recognised osteoarthritis scale. Results Among 266 studies published until May 2021, nine met our inclusion criteria. A total of 239 patients (274 knees) were included in our study. The follow-up ranged from 6 to 24 months. Six studies had a control group (only one being placebo). All studies showed that SVF improved pain and functionality measured, in most cases, with the visual analogue scale and the Western Ontario and McMaster Universities Osteoarthritis Index. In addition, five studies reported an improvement in anatomical structures, as detected in MR images. However, the number of cells contained in SVF varied substantially between diff

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansOsteoarthritis, KneeStromal Vascular FractionInjectionsAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research